In addition, doxorubicin-based in situ vaccination strategy combined with anti-CTLA-4 and anti-OX40, an agonistic antibody against the stimulatory checkpoint molecule OX40, has been shown to improve T cell infiltration into distant tumors, leading to tumor eradication and increased survival [105]. Here, CTLA4 is linked to neoplasm.